Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

NEXT STORY
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
PREV STORY
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunology Market to Hit USD 158.69 Billion with 8.1% CAGR by 2028 Backed by Increasing Demand for Biosimilars Globally, reports Fortune Business Insights™

author_avatar
NASDAQ Market News

FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

Basel, 05 December - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the ...

author_avatar
NASDAQ Market News

Hospital/Medical Beds Market Worth USD 3.14 Billion by 2023, Says Meticulous Research®

LONDON, Sept. 03, 2018 (GLOBE NEWSWIRE) -- According to this latest publication from Meticulous ...

author_avatar
NASDAQ Market News